Symbol | Exchange | Currency |
|---|
Cytokinetics (NASDAQ:CYTK), Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled,...
Investing.com - Cytokinetics Inc (NASDAQ: CYTK) reported first quarter EPS of $-1.38, $0.18 worse than the analyst estimate of $-1.20. Revenue for the quarter came in at $4.61M...
In this tiresome up-every-day market, here are some relatively new stocks that continue to show verve. Of course, high-fliers in a richly-valued market are still...
1. BioCryst BioCryst Pharmaceuticals (NASDAQ:BCRX), in the biotech vaccine area, on Tuesday popped to 5.41, up 46 cents, or 9%, after reaching a midday high of 5.56, on 10.9...
1. Amyris (NASDAQ:AMRS) popped on Monday with good volume, gaining 81 cents, or 30%, to 3.49, after reaching a session high of 3.70, on 6.4 million shares traded. It broke out...
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. The Company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv , a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten, a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-136 an novel small molecule cardiac troponin activator.
| Average | 60.93 (+57.33% Upside) |
| High | 80.00 |
| Low | 41.00 |
| Price | 38.73 |
| No. of Analysts | 15 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Buy | Buy |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Sell | Sell |
| Summary | Buy | Strong Buy | Strong Buy | Neutral | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 73.66 | 77.14 | 73.58 | -1.22 | -1.63% | 4.50M | NASDAQ | |||
| 10.19 | 10.64 | 10.09 | -0.32 | -3.04% | 18.86M | NYSE | |||
| 11.76 | 11.82 | 11.36 | +0.46 | +4.07% | 185.98K | NYSE | |||
| 3.86 | 3.956 | 3.79 | +0.040 | +1.05% | 11.02K | NASDAQ | |||
| 13.20 | 13.30 | 12.80 | -0.2 | -1.48% | 2.38K | OTC Markets | |||
| 4.71 | 5.12 | 4.13 | +1.03 | +27.99% | 24.34M | NASDAQ | |||
| 1.25 | 1.32 | 1.25 | 0.00 | 0.00% | 59.80K | NASDAQ | |||
| 3.00 | 3.00 | 3.00 | 0.00 | 0.00% | 0.00 | OTC Markets | |||
| 10.00 | 10.08 | 9.99 | -0.02 | -0.20% | 47.80K | NYSE | |||
| 0.0001 | 0.0001 | 0.0001 | 0.00 | 0.00% | 4.20K | OTC Markets | |||
| 14.37 | 14.60 | 14.11 | +0.23 | +1.63% | 3.36M | NYSE | |||
| 148.31 | 155.68 | 147.54 | -4.72 | -3.08% | 1.55M | NYSE | |||
| 2.64 | 2.68 | 2.60 | -0.010 | -0.38% | 52.48K | NASDAQ | |||
| 15.67 | 16.44 | 15.56 | -0.14 | -0.89% | 7.08M | NASDAQ | |||
| 16.13 | 16.16 | 16.09 | +0.01 | +0.06% | 6.93K | NYSE |